Conclusion: Women with scoliosis showed significantly higher fracture risk for major osteoporotic fractures and for hip fractures compared to those without scoliosis.

References:
[7] Chaklin VD. Pathology, clinical manifestation and treatment of the scoliosis, 1st congress of the union of the orthopedists and traumatologists, Moscow: Medgiz, 1957 – T. 2. – p 798

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4440

SAT0474

WHAT DETERMINES THE EFFECT OF THERAPY WITH DENOSUMAB ON BONE IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

P. Kovalenko1, I. Dydkina1, A. Smirnov1, E. Nasonov1, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: RANK-ligand is essential for osteoclast development, activation, and survival and it is a key mediator of increased osteoclast activity in rheumatoid arthritis (RA). Denosumab is a monoclonal antibody that binds RANK-ligand.

Objectives: The aim of this study was to evaluate the effects of denosumab on bone mineral density (BMD) and to define a contribution of factors: anamnesis, clinical/laboratory markers, glucocorticoids (GC) intake, etc. on the response to therapy with denosumab in women with RA and osteoporosis (OP).

Methods: 66 postmenopausal women (mean age 59.6±7.4) with RA (mean duration 17.7±10.4 years) and OP received s/c denosumab 60 mg every 6 months for 12 months. RF-positive was 72%, ACCP – 74% of patients. 34 (49%) patients continued GC. At baseline and after 12 months it was carried out the dual energy x-ray absorptiometry at 3 sites: lumbar spine (L1-L4), hip (HN) and distal forearm (DF) and x-ray of hands and feet (Sharp/van der Heijde (SVH) score). The Statistica 6.0 was used.

Results: After therapy it was noted the increase (p < 0.05) of BMD in L1-L4 and HN, a tendency to increase (p = 0.03) in L1-L4, HN and HF and a decrease in DF. Analysis of influence of factors showed that positive response on therapy in RA and OP was associated with RF-positivity. No new symptomatic fractures occurred in any participants at month 12.

Conclusion: After 12 months of therapy with denosumab in postmenopausal women with RA and OP it was shown the significant increase of BMD in L1-L4 and HF, a tendency to increase in DF. The mean change of BMD (%) after 12 months was +4.6% in L1-L4, at HN +2.8%, at HF +0.7%, Positive response on denosumab (BMD) was noted in 89% patients at L1-L4, 67% - at HN and 60% - at DF. Analysis of influence of factors showed that positive response on therapy in RA and OP was associated with RF-positivity. The distinct contribution to the negative response in L1-L4 and HF was associated with GC intake (previous intake more than 3 months in the anamnesis) and purpose of the GC after menopause onset. Also, negative response in RA and OP correlated with increase in erosion score and total SVH score.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2301

SAT0475

DENOSUMAB VERSUS ORAL BISPHOSPHONATE FOR OSTEOPOROSIS IN LONG-TERM GLUCOCORTICOID USERS: A 12-MONTH RANDOMIZED CONTROLLED TRIAL

C. C. Mok1, L. Y. Ho1, K. L. Chan1, S. M. Tse on behalf of N/A.1 Tuen Mun Hospital, Medicine, Hong Kong, Hong Kong (SAR)

Background:
Objectives: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.

Methods: Patients receiving long-term prednisolone treatment for medical illnesses were recruited. Inclusion criteria: (1) adult patients ≥18 years of age; (2) prednisolone ≥2.5mg/day for ≥1 year. Exclusion criteria: (1) previous use of osteoporosis teriparatide; (2) plan for pregnancy; (3) metabolic bone disease or unexplained hypocalcemia; (4) renal insufficiency. Participants were randomized to receive either: (1) DEN (60mg subcutaneously every 6 months); or (2) ALN (70mg/week). Calcium (Caltrate 3000mg/day) and vitamin D3 (cholecalciferol 1000IU/day) was given. BMD (femoral neck, total hip, lumbar spine) at month 0, 6 and 12 months were performed. Markers of bone turnover (serum P1NP and CTX) were also assayed at the same time points. The primary outcome was the difference of lumbar spine BMD change at month 12 between the two groups.

Results: 139 subjects were recruited (age 50.0±12.7 years): 69 assigned DEN and 70 assigned ALN. Underlying medical diseases: SLE (81%), RA (9.4%) and myositis (5%). Prednisolone dose at entry was 5.7±2.1mg/day. 56% of female patients were postmenopausal. 73(53%) of patients were osteoporotic (T score <-2.5) at the hip, femoral neck or lumbar spine. The mean body mass index (BMI) was 23.1±4.1kg/m2 (11% patients had BMI>18kg/m2). 82(59%) patients were naive to bisphosphonats. Pre-existing fragility or vertebral fracture was present in 19 (14%) patients and 18 patients (13%) had a family history of fractures. Baseline demographic data, osteoporotic risk factors, and BMD at various sites were not significantly different between the two groups at entry. At month 12, a significant gain in BMD at the lumbar spine (+3.5±2.2%; p<0.001) and the hip (+0.9±2.8%; p<0.01) was observed in DEN-treated patients, whereas the hip and femoral neck change was –0.2±2.5% (p=0.001) and +1.6±2.7% (p<0.001) in the ALN group. The spinal BMD at month 12 was significantly higher in the DEN than ALN group after adjustment for BMD values at baseline, age, sex and other osteoporosis risk factors that included smoking, drinking, cumulative steroid doses in one year, BMI, menopausal status and personal history of fracture (p=0.045). The differences in hip and femoral neck BMD were not significantly different between the two groups after adjustment for the same confounding factors. No new symptomatic fractures occurred in any participants at month 12. Adverse events were similar in frequency between the two treatment arms. Major infective episodes were uncommon (0.08/patient/year) and similar in the two groups. Minor upper gastrointestinal symptoms and non-specific dizziness were numerically more common in the ALN but arthralgia, minor infections (eg. upper respiratory tract) and new hypertension was more commonly reported in the ALN group. Three patients from ALN and 2 patients from DEN group were withdrawn from the study because of non-compliance but none withdrew because of adverse events.

Conclusion: In patients receiving long-term glucocorticoids, DEN is superior to ALN in raising the spinal BMD after 12 months’ treatment. Both DEN and ALN were well tolerated.

Acknowledgments: NIL

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4679

SAT0476

COMPLIANCE AND PERSISTENCE OF ANTI-OSTEOPOROTIC TREATMENTS IN PATIENTS WITH HIP FRACTURE

S. Paredes1, M. Guinovart2, A. Basco2, C. Llop3, 1Hospital Universitari Sant Joan de Reus, Department of Rheumatology, Reus, Spain; 2CatSalut, Pharmacy Unit, Tarragona, Spain

Table. Influence of various factors on the response to therapy with denosumab after 12 months of treatment (n=66)

<table>
<thead>
<tr>
<th>DXA site</th>
<th>Positive response on therapy associated with</th>
<th>Negative response on therapy associated with</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1-L4</td>
<td>- GC intake (&gt; 3 months in anamnesis) (p = 0.034); the beginning of GC intake after menopause (p = 0.023); GC intake (&gt; 3 months in anamnesis) (p = 0.024)</td>
<td></td>
</tr>
<tr>
<td>Hip neck</td>
<td>higher concentration of RF (initially and in dynamics) (p &lt; 0.05); the beginning of menopause later than RA onset (p = 0.024)</td>
<td></td>
</tr>
<tr>
<td>Forearm (distal 1/3)</td>
<td>RF-positivity (p = 0.02)</td>
<td>back correlates with increase in erosion score and total SVH score: r = -0.369 (p &lt; 0.05)</td>
</tr>
</tbody>
</table>